financetom
Business
financetom
/
Business
/
Pyxus Q2 operating income rises 41% on margin improvement
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Pyxus Q2 operating income rises 41% on margin improvement
Nov 12, 2025 4:23 AM

Overview

* Pyxus ( PYYX ) Q2 fiscal 2026 sales rise slightly to $570.2 mln from $566.3 mln last year

* Company's Q2 operating income rises to $46.7 mln, driven by improved margins

* Adjusted EBITDA for Q2 fiscal 2026 increases to $54.8 mln from $44.3 mln last year

Outlook

* Company raises full-year sales guidance to $2.4 bln-$2.6 bln

* Pyxus ( PYYX ) tightens full-year adjusted EBITDA guidance to $215 mln-$235 mln

* Company anticipates steady demand but prepares for potential oversupply

Result Drivers

* CROP VOLUMES - Larger crop volumes in Africa and South America drove sales increase, despite lower leaf product revenues due to lower prices

* GROSS MARGIN EXPANSION - Improved product mix and increased processing volumes led to gross margin expansion

* OPERATING INCOME - Operating income rose due to improved margin performance

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Net -$902,00

Income 0

Q2 $54.80

Adjusted mln

EBITDA

Q2 Gross $87.79

Profit mln

Q2 $46.73

Operatin mln

g Income

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Amgen aims to treat liver, kidney diseases with obesity drug
Amgen aims to treat liver, kidney diseases with obesity drug
Sep 6, 2024
By Puyaan Singh Sept 4 (Reuters) - Amgen ( AMGN ) will test its obesity drug candidate in patients at risk of weight-related conditions such as heart, liver and kidney diseases in its late-stage trial, the company's CEO Robert Bradway said on Wednesday. Speaking at a Morgan Stanley healthcare conference, Bradway described MariTide as a next-generation obesity drug due to...
Reports of dollar's demise are greatly exaggerated, JPMorgan says
Reports of dollar's demise are greatly exaggerated, JPMorgan says
Sep 6, 2024
LONDON (Reuters) - Suggestions that the dollar's dominance of the global financial system is ending are wide of the mark, JPMorgan said on Wednesday, despite some dramatic signs of change in commodity markets and certain trading blocs. China's rise and the use of economic sanctions on the likes of Russia mean there is a trend of diversification away from the...
Axsome Therapeutics Says FDA Accepts Potential Migraine Treatment Resubmission
Axsome Therapeutics Says FDA Accepts Potential Migraine Treatment Resubmission
Sep 6, 2024
10:54 AM EDT, 09/04/2024 (MT Newswires) -- Axsome Therapeutics ( AXSM ) said Wednesday the US Food and Drug Administration has accepted the resubmission of its New Drug Application for AXS-07 to potentially treat migraine. The FDA has classified it as a Class 2 resubmission, with a Prescription Drug User Fee Act target action date of Jan. 31, 2025, the...
Knightscope Wins New Emergency Communication Contracts
Knightscope Wins New Emergency Communication Contracts
Sep 6, 2024
10:50 AM EDT, 09/04/2024 (MT Newswires) -- Knightscope ( KSCP ) said Wednesday it has obtained three new contracts for its emergency communication devices, or ECDs. The company said its authorized partner Colonial Electric sold four K1 Blue Light Towers to a client in New Jersey. Universities in California and Texas also decided to expand existing contracts to include long-term...
Copyright 2023-2026 - www.financetom.com All Rights Reserved